[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355884-105":59,"doc-detail-355884-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-impact-of-trop2-in-adenocarcinoma-of-the-esophageal-junction-and-stomach","Prognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach","","Adenocarcinoma of the esophageal junction and stomach (AEG/S) has poor outcomes, motivating identification of actionable biomarkers. Trophoblast cell surface protein 2 (TROP2), a targetable antigen, is investigated for its clinicopathological and survival correlations in AEG/S. In 250 surgically treated patients, TROP2 expression is quantified by immunohistochemistry on tissue microarrays from primary tumors and lymph node metastases, relating expression intensity to overall survival and tumor features.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-impact-of-trop2-in-adenocarcinoma-of-the-esophageal-junction-and-stomach/355884/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-impact-of-trop2-in-adenocarcinoma-of-the-esophageal-junction-and-stomach/355884.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was TROP2 expression measured in AEG/S patients?","Question",{"text":112,"@type":113},"TROP2 expression was assessed in a cohort of 250 AEG/S patients using immunohistochemistry on tissue microarrays from primary tumors and lymph node metastases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study find about TROP2 frequency in tumors and lymph node metastases?",{"text":117,"@type":113},"TROP2 was expressed in 86% of primary tumors and 81.3% of lymph node metastases.",{"name":119,"@type":110,"acceptedAnswer":120},"How does TROP2 expression intensity relate to patient survival?",{"text":121,"@type":113},"Higher TROP2 expression intensity was associated with worse overall survival, with low, medium, and high intensity showing progressively shorter survival times.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355884,1791165790,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Clinical and Translational Oncology (2026) 28:2959–2966  \n[https://doi.org/10.1007/s12094-025-04203-6](https://doi.org/10.1007/s12094-025-04203-6)  \nPrognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach  \nAnselm Pittrof1 · Alexander Arnold2 · Severin Daum3 · Jonas Staudacher3 · Erika Berg2 · Michael Hummel2 · David Horst2 · Beate Rau4 · Ulrike Stein5 · Lisa Marie Eich2 · Christoph Treese3  \nReceived: 2 November 2025 / Accepted: 22 December 2025 / Published online: 14 January 2026 © The Author(s) 2026  \nAbstract  \nIntroduction Adenocarcinoma of the esophageal junction and stomach (AEG/S) remains one of the deadliest cancers worldwide. New treatment options are urgently needed. A new target could be trophoblast cell surface protein 2 (TROP2), which is expressed in a variety of solid tumors and can be targeted, e.g., by sacituzumab govitecan, which has shown promising results in triple-negative breast cancer. This study investigates the expression of TROP2 in patients with AEG/S and correlates its expression with clinical and histopathological endpoints.  \nMethods TROP2 expression was assessed in a cohort of 250 patients who underwent primary surgery for AEG/S. Immunohistochemistry was performed on tissue microarrays constructed from primary tumors and lymph node metastases to quantify TROP2 expression intensity. Clinical variables, including overall survival and patient demographics, as well as tumor-specific characteristics such as stage and grade, were correlated with TROP2 expression to evaluate its potential prognostic relevance in AEG/S.  \nResults TROP2 was expressed in 86% of primary tumors and 81.3% of lymph node metastases. The intensity of TROP2 expression (low vs. medium vs. high) was correlated negatively with overall survival (p\u003C 0.05, 70.9 months vs. 54.2 months vs. 39.5 months), lymphatic invasion (p = 0.05, V = 0.138), and higher grading (p = 0.037, V = 0.143) . The intensity of TROP2 expression in lymph node metastases and primary tumors correlated significantly (p \u003C 0.001, ρ = 0.444) . There was a non-significant increase in positive lymphonodal status (p = 0.093, V = 0.138) in patients with higher TROP2 expression. Conclusion In Caucasian AEG/S patients, TROP2 is expressed in the majority of cases. TROP2 expression intensity itself has an impact on survival, which could be explained by a more aggressive phenotype, which leads to lymphatic invasion and lymph node metastasis.  \nKeywords TROP2 · Trophoblast cell surface antigen 2 · Gastric cancer · Esophageal cancer · AEG/S · Sacituzumab govitecan  \nL. M. Eich and C. Treese—these authors are equally contributed.  \n* Anselm Pittrof[anselm.pittrof@charite.de](anselm.pittrof@charite.de)  \n1 Department of Hematology, Oncology and Cancer Immunology, Charité -Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany  \n2 Institute of Pathology, Charité -Universitätsmedizin Berlin, Berlin, Germany  \n3 Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité -Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany  \n4 Department of Surgery, Charité -Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Mitte, Berlin, Germany  \n5 Experimental and Clinical Research Center, Charité – Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany  \nIntroduction  \nAdenocarcinomas ofthe esophagogastric junction and stomach (AEG/S) remain a major global health burden, accounting for more than one million deaths annually, with the highest incidence observed in Asian populations [1] . Despite the introduction of targeted therapies—including anti-HER2 [2], anti-VEGFR2 [3], anti-Claudin 18.2 [4, 5], and anti–PD-L1 agents [6]—prognosis remains poor, with approximately half of the patients surviving beyond 1 year after diagnosis [7] .  \nTrophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein involved in calcium signaling and e","cbCaievh5kUOZRfP","https://ap.wps.com/l/cbCaievh5kUOZRfP","pdf",1507402,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n# Introduction\n## TROP2 as a cancer-associated target\n## Sacituzumab govitecan background\n## Rationale for evaluating TROP2 in AEG/S","[{\"question\":\"How was TROP2 expression measured in AEG/S patients?\",\"answer\":\"TROP2 expression was assessed in a cohort of 250 AEG/S patients using immunohistochemistry on tissue microarrays from primary tumors and lymph node metastases.\"},{\"question\":\"What did the study find about TROP2 frequency in tumors and lymph node metastases?\",\"answer\":\"TROP2 was expressed in 86% of primary tumors and 81.3% of lymph node metastases.\"},{\"question\":\"How does TROP2 expression intensity relate to patient survival?\",\"answer\":\"Higher TROP2 expression intensity was associated with worse overall survival, with low, medium, and high intensity showing progressively shorter survival times.\"}]","Prognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach | PDF",1790121523]